3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Fluorouracil
14
pembrolizumab
13
Paclitaxel
13
Oxaliplatin
13
Leucovorin
10
Carboplatin
9
Radiotherapy
8
Capecitabine
8
Trastuzumab
7
Nivolumab
7
Drug Therapy
7
Cisplatin
7
Radiation
6
Esophagectomy
6
Taxes
5
Specimen Handling
5
Irinotecan
4
trastuzumab deruxtecan
3
tislelizumab
3
patritumab deruxtecan
3
Surgical Procedures, Operative
3
Radiotherapy, Intensity-Modulated
3
Immunotherapy
3
Blood Specimen Collection
3
zanidatamab
2
ulixertinib
2
trastuzumab biosimilar HLX02
2
relatlimab
2
durvalumab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Histamine H2 Antagonists
×
90 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled